摘要
目的评价曲尼司特胶囊治疗特应性皮炎的安全性和有效性。方法采用多中心、随机双盲、安慰剂平行对照的研究方法,将入选患者随机分为治疗组和对照组,分别接受曲尼司特和安慰剂治疗,于治疗前(基线)及治疗后第1~3周访视1次,连续4周。主要疗效指标为SCORAD,次要疗效指标包括炎症性皮损范围指数、瘙痒的视觉模拟评分及影响睡眠评分等。结果共144例特应性皮炎患者(曲尼司特治疗组和安慰剂对照组各72例)参加本研究,其中139例(曲尼司特治疗组70例,安慰剂对照组69例)纳入疗效可评估分析集(FAS)。研究结束根据SCORAD下降进行评价时,治疗组和对照组的有效率分别为61.43%和24.64%,两组间差异有统计学意义(P=0.0001)。用药2、3、4周后,SCORAD评分、瘙痒的视觉模拟评分及影响睡眠评分等指标均显著下降,两组比较差异有统计学意义(P〈0.05)。治疗组少数患者出现胸闷、嗜睡等现象。两组不良事件的发生率为8.45%和11.43%,两组差异无统计学意义。结论曲尼司特胶囊治疗特应性皮炎安全有效。
Objective To evaluate the safety and efficacy of tranilast capsule in the treatment of atopic dermatitis. Methods This multicenter, randomized, double-blind, parallel, placebo-controlled clinical trial was conducted at 3 research sites in China. Patients with atopic dermatitis were randomly assigned to 4 weeks of treatment with tranilast capsule or placebo three times daily. Efficacy evaluations were performed at baseline and at each weekly visit for 4 weeks. The primary efficacy parameter was the Severity Scoring of Atopic Dermatitis ( SCORAD ). Secondary parameters included the extent of skin inflammation index, visual analog scores of pruritus, and sleep disturbance score. Results A total of 144 patients with atopic dermatitis were enrolled in the study. Of these, 139 patients ( 70 on tranilast and 69 on placebo ) who received at least one dose of study medication and completed at least one efficacy evaluation were included in the full analysis set ( FAS ). At the end of study, tranilast had significantly greater efficacy than placebo as assessed by improvement in SCORAD ( 61.43% vs 24.64%, P = 0.0001 ). Furthermore, tranilast-treated patients experienced significantly greater improvement than placebo-treated patients in SCORAD, visual analog scores of pruritus, and sleep disturbance' score at weeks 2, 3, and 4 ( P 〈 0.05 ). There was no significant difference in the incidence of adverse events between the tranilast and placebo groups ( 8.45% vs 11.43%, P 0.5864 ). The adverse events in the tranilast-treated group included chest tightness, drowsiness, and eyelid edema, etc. Conclusion Tranilast capsule is safe and effective in the treatment of atopic dermatitis.
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2007年第1期38-41,共4页
Chinese Journal of Dermatology
关键词
皮炎
特应性
曲尼司特
随机对照试验
Dermatitis, atopic
Tranilast
Randomized controlled trails